All In Biotech

Investigational drug · Phase 2

IMA401

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "IMA401"

First trial start

2023

Aug 9, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "IMA401", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Refractory Cancer
  • Recurrent Cancer
  • Solid Tumor, Adult
  • Cancer

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "IMA401" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Refractory Cancer

  • anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials

    Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult

  • Checkpoint InhibitorPhase 22 trials

    EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms

  • Monoclonal antibodyPhase 22 trials

    Immunocore Ltd · Cancer, HLA-A*02:01-positive, Refractory Cancer

  • HST-1011Phase 21 trial

    HotSpot Therapeutics, Inc · Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer

  • IMA402Phase 21 trial

    Immatics Biotechnologies GmbH · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.